Cargando…

Impaired dopamine release in Parkinson’s disease

Parkinson’s disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlyi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cramb, Kaitlyn M L, Beccano-Kelly, Dayne, Cragg, Stephanie J, Wade-Martins, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393405/ https://www.ncbi.nlm.nih.gov/pubmed/36864664 http://dx.doi.org/10.1093/brain/awad064

Ejemplares similares

Calcium dysregulation combined with mitochondrial failure and electrophysiological maturity converge in Parkinson’s iPSC-dopamine neurons
por: Beccano-Kelly, Dayne A., et al.
Publicado: (2023)

Hyperexcitability in young iPSC-derived C9ORF72 mutant motor neurons is associated with increased intracellular calcium release
por: Burley, Sarah, et al.
Publicado: (2022)

Impaired intracellular trafficking defines early Parkinson's disease
por: Hunn, Benjamin H.M., et al.
Publicado: (2015)

Leptin: A Novel Therapeutic Target in Alzheimer's Disease?
por: Beccano-Kelly, Dayne, et al.
Publicado: (2012)

GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model
por: Roberts, Bradley M., et al.
Publicado: (2020)

Axonal Modulation of Striatal Dopamine Release by Local γ-Aminobutyric Acid (GABA) Signalling
por: Roberts, Bradley M., et al.
Publicado: (2021)

Impaired dopamine metabolism in Parkinson’s disease pathogenesis
por: Masato, Anna, et al.
Publicado: (2019)

From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson’s Disease: Lessons From LRRK2
por: Mancini, Andrea, et al.
Publicado: (2020)

Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter
por: Condon, Mark D., et al.
Publicado: (2019)

Impairment of Macroautophagy in Dopamine Neurons Has Opposing Effects on Parkinsonian Pathology and Behavior
por: Hunn, Benjamin H.M., et al.
Publicado: (2019)

Inhibition of Nigrostriatal Dopamine Release by Striatal GABA(A) and GABA(B) Receptors
por: Lopes, Emanuel F., et al.
Publicado: (2019)

Dopamine Receptors and Parkinson's Disease
por: Hisahara, Shin, et al.
Publicado: (2011)

Convergent pathways in Parkinson’s disease
por: Cherubini, Marta, et al.
Publicado: (2017)

Calbindin-D28K Limits Dopamine Release in Ventral but Not Dorsal Striatum by Regulating Ca(2+) Availability and Dopamine Transporter Function
por: Brimblecombe, Katherine R., et al.
Publicado: (2019)

Role of dopamine in the pathophysiology of Parkinson’s disease
por: Zhou, Zhi Dong, et al.
Publicado: (2023)

Palmitoylation of δ-catenin by DHHC5 Mediates Activity-Induced Synapse Plasticity
por: Brigidi, G. Stefano, et al.
Publicado: (2014)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease
por: Benkert, Julia, et al.
Publicado: (2019)

Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice
por: Beccano-Kelly, Dayne A., et al.
Publicado: (2014)

LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function
por: Sloan, Max, et al.
Publicado: (2016)

Reduced striatal dopamine release during motor skill acquisition in Parkinson’s disease
por: Kawashima, Shoji, et al.
Publicado: (2018)

Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice
por: Volta, Mattia, et al.
Publicado: (2017)

Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease
por: Park, Ariane, et al.
Publicado: (2011)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Impaired dopamine metabolism is linked to fatigability in mice and fatigue in Parkinson’s disease patients
por: Scheffer, Débora da Luz, et al.
Publicado: (2021)

A review of ropinirole prolonged release in Parkinson’s disease
por: Nashatizadeh, Muhammad M, et al.
Publicado: (2009)

Intracerebroventricular dopamine for Parkinson's disease
por: Devos, David, et al.
Publicado: (2017)

The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis
por: Booth, Heather D.E., et al.
Publicado: (2017)

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
por: Weintraub, Daniel, et al.
Publicado: (2023)

Pomegranate Juice Ameliorates Dopamine Release and Behavioral Deficits in a Rat Model of Parkinson’s Disease
por: Kujawska, Małgorzata, et al.
Publicado: (2021)

Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients
por: Trujillo, Paula, et al.
Publicado: (2022)

Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease
por: Dunn, Amy R., et al.
Publicado: (2017)

Dopamine Signaling in Dorsal Versus Ventral Striatum: The Dynamic Role of Cholinergic Interneurons
por: Threlfell, Sarah, et al.
Publicado: (2011)

Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging
por: Heng, Nicholas, et al.
Publicado: (2023)

Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson’s disease
por: Sandor, Cynthia, et al.
Publicado: (2017)

Replacing Dopamine Neurons in Parkinson’s Disease: How did it happen?
por: Björklund, Anders, et al.
Publicado: (2017)

Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
por: López, Tessy, et al.
Publicado: (2011)

Dopamine and Acetylcholine, a Circuit Point of View in Parkinson’s Disease
por: Rizzi, Giorgio, et al.
Publicado: (2017)

Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of α-Synuclein and Cholesterol
por: Threlfell, Sarah, et al.
Publicado: (2021)

Mitochondrial dysfunction and mitophagy defects in LRRK2-R1441C Parkinson’s disease models
por: Williamson, Matthew G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_is43rqikk2drj8l32h90q03lau